AlmirallShare, the open innovation platform of Almirall, S.A. (ALM) launches today a new call with the aim of finding novel targets and concepts in the treatment of dermatological diseases. Targets of interest may be proteins or nucleic acids whose function can be modulated by a small molecule or biological therapy that have a scientific rationale in a dermatological disease. Concepts may be mechanisms, pathways, or cell players not previously linked to a disease of interest.
The call is open from October 10th, 2018 to February 28th, 2019 and is addressed to universities, research centers, start-ups, biotechs and pharma companies all over the world with an interest in pharmaceutical R&D.
Scientists from these organisations are invited to submit their proposals. All submitted projects are evaluated in a pre-defined period of time and those that are accepted are eligible for a research grant up to 100.000€. Selected proposals may also benefit from scientific support from Almirall’s team, access to Almirall’s technology platforms and pharmacological tools to assist them on target validation, and specialised advice for intellectual property matters, if requested.
Since its launch in September 2017, AlmirallShare has drawn the attention of Scientists from universities, research centers and start-ups interested on dermatological research. About 380 scientists from all continents have subscribed to the platform and over 120 proposals have been received to date. A selection of innovative ideas were accepted and they are currently being developed.
“Given the results we had with our previous AlmirallShare calls, we are really looking forward to launch this new call. We are expecting to collaborate with experts worldwide to identify novel targets that may form the basis for new medicines. It is an opportunity for both parts, Almirall and the Research partners, to develop innovative therapies for patients suffering from dermatological diseases.” said Maribel Crespo, AlmirallShare Leader.
For more information, please visit almirall.com.